©2024 Stanford Medicine
Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery
Not Recruiting
Trial ID: NCT02550145
Purpose
The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial
glucose reductions after bariatric surgery in a subset of patients who have severe
symptomatic hypoglycemia.
Official Title
The Role of GLP-1 in Mediating Glucose Reductions After Bariatric Surgery
Eligibility
Inclusion Criteria:
- Men and women ages 18-65
- BMI 25-40 with a clinical diagnosis of severe symptomatic hypoglycemia after bariatric
surgery
Exclusion Criteria:
- Acute medical illness, such as acute bacterial or viral syndrome, febrile illness,
acute abdominal symptoms, orthopedic injury within one week
- History of cardiac failure, renal insufficiency (estimated Crcl<30cc/min), hepatic
insufficiency, chronic obstructive pulmonary disease, anemia (Hct<30%), or
uncontrolled hypertension (SBP>160 or DBP>100)
- Pregnancy
- Use of medications that affect glucose metabolism
- Fasting glucose >150 or HbA1c>7.5 on Metformin
- Women of childbearing potential (will have a pregnancy test, in addition use of
abstinence for at least one month prior to study or use two types of contraceptives,
hormonal implant or Depo Provera)
- Active, uncontrolled psychiatric disease
- Participating in other studies or have received investigational medications within the
past month or 5 half-lives of the drug, whichever is longer.
Intervention(s):
drug: Exendin (9-39)
other: Placebo
drug: Exendin (9-39)
other: Placebo
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Colleen Craig, M.D.
650-350-2153